secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2025-10-21T23:59:59+00:00
Accession:  0001193125-25-245093
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera sells avasopasem/rucosopasem assets to Biossil for $3.5M upfront, up to $105M milestones
--------------------------------------------------------------------------------

- Biossil Inc. acquires all of Galera's dismutase mimetic assets, including avasopasem (GC4419) and rucosopasem (GC4711).
- Upfront payment of $3,500,000; potential regulatory/commercial milestones and contingent value rights total up to $105,000,000.
- Biossil assumes rights and obligations under the 2018 Clarus IV Galera Royalty agreement (affiliated with Blackstone Life Sciences).
- Purchase Agreement contains customary representations, warranties, and covenants; filing of full agreement will follow in next Form 10-Q.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312525245093/0001193125-25-245093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312525245093/d96389d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-245093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer